Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorTodd C. Lee MD MPH FIDSA
About this trial
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Eligibility criteria
Qualifiers
Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);
Patient or healthcare proxy provide informed consent.
Disqualifiers
Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis < 90 days according to the treating team;
Patient requires intensive care but has a do not resuscitate order precluding transfer;
Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);
Organism tests as rifampin resistant;
Trial design
Treatments tested in this trial
- Rifampin
- No rifampin
Treatment groups
330 Participants
are divided into 2 treatment groupsSponsors and collaborators
Todd C. Lee MD MPH FIDSA
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor institution
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator
University of Melbourne
Collaborator
The Peter Doherty Institute for Infection and Immunity
Collaborator
Source ClinicalTrials.gov